Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis - Wikidata - wikimedia - TriplyDB

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

http://www.wikidata.org/entity/Q28260587

about

Benefits versus risks of latest therapies in multiple sclerosis: a perspective review Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Treating multiple sclerosis with monoclonal antibodies: a 2013 update.Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease.Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.The use of immune modulating drugs for the treatment of multiple sclerosis.Alemtuzumab in the treatment of multiple sclerosis.Monoclonal antibodies in neuroinflammatory diseases.Disease modification in multiple sclerosis: an update.Novel immunomodulatory approaches for the management of multiple sclerosis.Current evaluation of alemtuzumab in multiple sclerosis.Novel therapeutic options for multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Drug safety evaluation of alemtuzumab for multiple sclerosis.IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis.Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?Immune regulation by CD52-expressing CD4 T cells.Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.Graves' orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia - side effect of alemtuzumab therapy?

P2860

Q26999417-769F03E3-F9AC-43CB-9B3C-AF30C1FCDC65 Q33407411-592691F5-D168-4611-92B3-AEB1E3CDDF3B Q33408049-F631FF36-4BEC-42F6-88FC-CAE7DB4FFA91 Q34330211-D2E99129-BDE7-4A7F-80E8-155A30559CBD Q35634116-07D15980-4D18-4487-9B3A-AFB5C54A1ED9 Q36672726-6B4E6CCE-D33E-4B94-90F0-753912976834 Q37577290-58B23D62-A2AC-40E4-9BC0-1B5FFC9B69F6 Q37649028-90042CCC-C341-423D-83D2-9700A41D0F05 Q38092121-968CC7BC-00C5-4FE2-AE6A-99326566767E Q38150823-66026408-BA8F-44E0-9637-8157F035C59A Q38156608-E52798A2-C472-4A13-9CF2-859466C46CF1 Q38167350-E5FB693E-60E9-4537-96E4-3246507D6862 Q38170129-F5D0F78E-5B56-4A6D-A969-28D5E3C26899 Q38172961-C19F8D14-2F59-4B0E-AD46-D1E9E5A1D08A Q38220740-E04F6A3F-6153-487F-B576-E9911A7C541F Q38617794-5D72D47E-2242-4D43-A585-7D5D413EF751 Q38635412-5E0FA3C8-45BC-4E39-AAF9-C58139DACAAD Q38837090-F09E6040-584D-4581-BEDE-415DF9D732D5 Q39025968-E2793DF7-3979-4B92-8EDC-61A9FA6915F5 Q43073589-3C9A93C7-FBA8-425D-A1DA-D9C9E29CB8EE Q55129131-6A2AB598-2C58-4151-A3F8-AAEAD939B9B8

P2860

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

http://www.wikidata.org/entity/Q28260587

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@ast

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@en

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@nl

type

label

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@ast

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@en

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@nl

prefLabel

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@ast

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@en

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@nl

P1433

Q28260587-C9EC9EA4-50BD-49BC-B3F8-4F12C3386B24

P1476

Q28260587-056EAC39-892B-4AB7-A25F-1F867848BD1E

P2093

Q28260587-557141EF-42DA-4FE1-B3E8-AE85CA9134F2

Q28260587-DEB1447E-3C93-4FE3-B409-5C94A1DE0288

Q28260587-F6BCAA02-378A-45FD-A7FC-9084C1F4B478

P2860

Q28260587-009712EB-3608-463F-BD60-66C90A34A6E8

Q28260587-163BE48C-2F31-4985-BC28-5055CCBC06AB

Q28260587-1D984D46-0871-4835-8F73-0100F524DB13

Q28260587-255A6837-72E5-4B87-974D-31AB6BDFC041

Q28260587-3BA735C9-785E-4B1B-821C-E9882BCC4CC1

Q28260587-4CDA7092-9C91-4CB7-85E6-9A17A5370771

Q28260587-54814525-6306-4C96-825B-648015F71BA9

Q28260587-5688648E-9200-4EFC-AF82-663346EF57CB

Q28260587-58DD23FF-01D0-4CFD-90DE-ED4ABFD6B422

Q28260587-A2F7B626-B617-4D45-9813-FD109EEC83BC

P304

Q28260587-3A301BD0-4459-40CF-B0A2-3469B37EE3D6

P31

Q28260587-82A9763E-677D-4EFB-B7FC-C9B684BCBE08

P356

Q28260587-DA592973-9E93-45E7-BDED-53E8590DD392

P407

Q28260587-E6E78038-CD05-47C5-A67F-B432B2755D5A

P433

Q28260587-EE21787B-5272-4B01-90DB-90DA122916EB

P478

Q28260587-D59428BB-1CEF-4ACF-96BC-5FC7A957C770

P577

Q28260587-FC3D4CCC-74B2-47D5-AB6C-2AB0DA3071FB

P698

Q28260587-E727B76E-0BE7-4A2C-A83E-5B084D13FB5B

P921

Q28260587-6BAF4A4B-6A51-416D-9A75-53EBFB3EA632

P356

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@en

P2093

Alastair Coles

http://www.w3.org/2001/XMLSchema#string

Joanne Jones

http://www.w3.org/2001/XMLSchema#string

Lisa Costelloe

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Acquired autoimmune thrombocytopenia post-bone marrow transplantation for severe combined immunodeficiency.

Homeostatic expansion of T cells during immune insufficiency generates autoimmunity.

Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice.

The new paradigm of T-cell homeostatic proliferation-induced autoimmunity.

An autoimmune disease with multiple molecular targets abrogated by the transgenic expression of a single autoantigen in the thymus.

Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells.

Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation.

Autoimmunity during lymphopenia: a two-hit model.

P304

335-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERN.12.5

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22364332

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis